Cipla Sees Growth In Product-Based Alliances; In Deal With Teva For Inhalers In Russia
This article was originally published in PharmAsia News
India’s second largest drug maker draws newer strategies to keep pace with emerging markets’ growth momentum, Cipla Chairman Yusuf Hamied tells PharmAsia News in an exclusive interview.
You may also be interested in...
MUMBAI - Cipla Ltd. Chairman Yusuf K. Hamied has tried to temper nagging speculation over a possible sell-off to a global company like Merck & Co. or Takeda Pharmaceutical Co. Ltd. He emphatically denied holding any negotiations and claimed he has never been approached for a potential transaction
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.